3.12 Prenatal Screening (NIPT, Serum Markers)
Key Takeaways
- NIPT analyzes cell-free DNA (cfDNA) in maternal plasma—largely placental in origin—to screen for common fetal aneuploidies; it is screening, not diagnostic
- Test performance concepts: high sensitivity/specificity for trisomy 21 in validated populations, but positive predictive value depends on prevalence (maternal age/prior risk); fetal fraction critically affects reliability
- False-positive or discordant NIPT results may stem from confined placental mosaicism, vanishing twin, maternal copy-number variation or mosaicism, and rarely maternal malignancy
- Serum marker screens (first-trimester combined, quad screen) use analytes ± nuchal translucency to modify aneuploidy and, for AFP-based screens, open neural tube defect risk—also screening only
- Screen-positive results require offer of genetic counseling and diagnostic confirmation (CVS/amnio); screen-negative results reduce but do not eliminate residual risk
3.12 Prenatal Screening (NIPT, Serum Markers)
Quick Answer: NIPT (cfDNA) screens maternal plasma for common aneuploidies using DNA that is largely placental. It is not diagnostic. Performance depends on fetal fraction and prior risk (PPV). Discordant positives can reflect CPM, vanishing twin, maternal CNV/mosaicism, or rarely maternal malignancy. Serum screens (combined first-trimester, quad) also modify risk only—confirm screen-positives with diagnostic procedures when the patient wants certainty.
Domain 3C expects crisp separation of screening vs diagnosis, correct counseling after a “positive NIPT,” and recognition of why cfDNA can disagree with the fetus.
Screening vs Diagnosis (Non-Negotiable Frame)
| Screening (NIPT, serum markers, many ultrasound soft markers) | Diagnosis (CVS, amniocentesis with chromosomal/molecular analysis) | |
|---|---|---|
| Purpose | Stratify probability | Determine fetal genotype/karyotype (within test limits) |
| Result language | High risk / low risk / positive / negative screen | Presence/absence of tested abnormality (or mosaic/uncertain) |
| Next step after positive | Offer diagnostic testing + counseling | Clinical management and decision support |
Exam trap: Telling a patient that NIPT “diagnosed Down syndrome.” Trisomy 21 on NIPT is a high-probability screen requiring confirmatory diagnostic testing before irreversible pregnancy decisions in standard counseling frameworks.
NIPT / cfDNA: Mechanism and Scope
Cell-free DNA in maternal blood includes maternal cfDNA plus placental trophoblast-derived DNA (often called “fetal fraction,” though the source is placental). Labs analyze counts or genotypes across chromosomes to detect over-/under-representation consistent with aneuploidy (commonly 21, 18, 13; sex chromosome aneuploidies and selected microdeletion panels vary by lab and indication).
Typical counseling points before draw:
- What conditions are included vs excluded (e.g., many single-gene disorders are not covered by standard aneuploidy NIPT).
- Possibility of no-call / low fetal fraction results, especially at earlier gestations, higher BMI, or certain aneuploidies.
- Incidental detection of maternal chromosomal findings or, rarely, clues to maternal neoplasm.
- Twin and vanishing-twin complexity.
Performance Concepts You Must Apply
Sensitivity / specificity describe how often the test correctly flags affected vs unaffected pregnancies in validation cohorts. For trisomy 21, published NIPT performance is generally excellent as a screen—but that is not the same as PPV.
Positive predictive value (PPV) = among screen-positives, the proportion truly affected. PPV falls when prevalence is low (e.g., young patient without other risk factors) even if sensitivity/specificity are high. Always contextualize a positive NIPT with prior risk (age, ultrasound, serum screen, personal/family history).
Negative predictive value (NPV) is typically high for common aneuploidies in general obstetric populations, which is why a low-risk NIPT is reassuring—but residual risk is not zero, and structural anomalies or conditions outside the panel remain possible.
| Concept | Counselor translation |
|---|---|
| Fetal fraction | Too low → no-call or unreliable result; redraw or alternative testing |
| Sensitivity | Ability to detect true aneuploidy when present |
| Specificity | Ability to call screen-negative when euploid |
| PPV | “If positive, how likely is the fetus affected?” — prevalence-dependent |
| NPV | “If negative, how likely is the fetus unaffected for the screened condition?” |
Why NIPT Can Be Wrong: Biologic False Positives / Discordance
Because cfDNA is placental-leaning, discordance with the fetus is expected biology—not merely “lab error.”
| Mechanism | What happens | Counseling implication |
|---|---|---|
| Confined placental mosaicism (CPM) | Aneuploid cell line in placenta but fetus euploid (or different) | Diagnostic testing (preferably amnio reflecting fetal cells) may be discordant with NIPT |
| Vanishing twin | cfDNA from a demised twin’s placenta persists | False positive or sex discordance; obtain early ultrasound history |
| Maternal CNV or mosaicism | Maternal chromosomal imbalance contributes to the cfDNA signal | May need maternal diagnostic workup; fetus may be unaffected |
| Maternal malignancy (rare) | Tumor cfDNA distorts genomic representation | Multiple aneuploidies / non-reportable patterns may prompt oncology evaluation pathways |
| Technical / statistical borderline calls | Low z-scores, low FF | Redraw, alternate screen, or diagnostic offer |
Worked scenario. A 28-year-old with unremarkable ultrasound has NIPT positive for monosomy X. PPV is lower than in a 40-year-old with cystic hygroma. Counsel prior-risk-adjusted interpretation, offer diagnostic confirmation, and mention CPM and maternal findings as reasons results can discord—without dismissing the finding.
Serum Marker Screening (Conceptual)
First-trimester combined screening typically uses pregnancy-associated plasma protein-A (PAPP-A), free β-hCG (or total hCG depending on protocol), and nuchal translucency (NT) ultrasound, sometimes with nasal bone or other markers, to produce aneuploidy risk figures.
Quad screen (second trimester) classically measures AFP, hCG, unconjugated estriol (uE3), and inhibin A to modify risk for trisomy 21/18 and uses AFP for open neural tube defect risk assessment. Patterns (e.g., high AFP → NTD/ventral wall concern; low uE3 in certain contexts) are interpretive clues for MFM—not standalone diagnoses.
| Screen | Timing (typical) | Strengths | Limits |
|---|---|---|---|
| NT ± first-trimester serum | ~11–13+ weeks | Early risk assessment; NT detects some structural clues | Screening only; NT requires quality ultrasound |
| Quad screen | ~15–22 weeks (lab-dependent) | Broad access; AFP for ONTD risk | Lower aneuploidy detection than NIPT for common trisomies in many comparisons; dating errors affect analytes |
| NIPT/cfDNA | From ~9–10 weeks (lab-dependent) | High detection for common aneuploidies as screening | Cost/access; placental source; panel limits; PPV issues |
Sequential, contingent, or serum-integrated protocols exist historically; know that NIPT has shifted first-line aneuploidy screening in many settings, while serum AFP still contributes ONTD risk information that standard aneuploidy NIPT does not replace.
After a Screen-Positive or No-Call Result
- Explain screening ≠ diagnosis; quote PPV language when available on the report.
- Review ultrasound for anomalies that raise or lower post-test risk.
- Offer diagnostic testing (CVS vs amnio—see 3.13) and genetic counseling time.
- For no-call: discuss redraw vs proceed to diagnostic testing vs alternative screen, especially if high prior risk.
- Avoid false reassurance from a subsequent normal ultrasound alone when NIPT was positive for aneuploidy—ultrasound can be normal in aneuploidy.
Master PPV + placental biology + screening-only language; those three themes dominate NIPT board items.
A patient receives a “positive” NIPT result for trisomy 21 and asks if the fetus has been diagnosed with Down syndrome. The most accurate response is:
Which biologic mechanism best explains a false-positive NIPT aneuploidy result when the fetus is later shown to be euploid on amniocentesis?
Why must genetic counselors discuss fetal fraction when reviewing NIPT?
Compared with NIPT for common aneuploidies, which statement about the second-trimester quad screen is most accurate at a conceptual level?